Autonomic Nervous System Drugs Practice Questions

Q: A patient with glaucoma and bronchial asthma presents with status asthmaticus. What causative agent might have precipitated this condition?

Timolol eye drop. **Explanation:** **1. Why Timolol is the Correct Answer:** Timolol is a **non-selective beta-blocker** ($\beta_1$ and $\beta_2$ antagonist) commonly used as first-line therapy for glaucoma to decrease aqueous humor production. Even when administered topically as eye drops, significant systemic absorption occurs via the nasolacrimal duct, bypassing first-pass metabolism. In patients with pre-existing bronchial asthma, the blockade of $\beta_2$ receptors in the bronchial smooth muscle leads to bronchoconstriction, which can precipitate life-threatening **status asthmaticus**. **2. Analysis of Incorrect Options:** * **Pilocarpine (Option A):** A direct-acting cholinergic agonist (miotic). While it can cause bronchoconstriction in theory, it is not a beta-blocker and is rarely associated with precipitating status asthmaticus compared to $\beta$-blockers. * **Betaxolol (Option C):** This is a **cardioselective ($\beta_1$) blocker**. Because it lacks significant $\beta_2$ antagonist activity, it is the safest beta-blocker for glaucoma patients who also have respiratory diseases (though it should still be used with caution). * **Levobunolol (Option D):** Like timolol, it is a non-selective beta-blocker. However, Timolol is the classic prototype and the most frequently cited agent in exam questions regarding this specific adverse interaction. **3. NEET-PG High-Yield Pearls:** * **Systemic Absorption:** To minimize systemic side effects of eye drops, patients should be taught **nasolacrimal occlusion** (pressing the inner canthus) for 1–2 minutes after instillation. * **Drug of Choice:** For a glaucoma patient with asthma, **Betaxolol** is the preferred beta-blocker, or alternative classes like Prostaglandin analogues (Latanoprost) should be used. * **Contraindications for Timolol:** Asthma, COPD, Bradycardia, and Second/Third-degree heart block.

Q: What is the mechanism of action of Silodosin?

Alpha antagonist. **Explanation:** **Silodosin** is a highly selective **alpha-1A (α1A) adrenergic receptor antagonist**. These receptors are primarily located in the smooth muscles of the prostate, bladder neck, and prostatic urethra. By blocking these receptors, Silodosin induces smooth muscle relaxation, which reduces resistance to urine flow and alleviates the dynamic component of urinary obstruction in patients with **Benign Prostatic Hyperplasia (BPH)**. **Analysis of Options:** * **Option A (Correct):** Silodosin belongs to the class of uroselective alpha-blockers. Unlike older agents like Doxazosin, Silodosin is highly specific for the α1A subtype, minimizing systemic side effects like hypotension. * **Option B:** Beta-antagonists (Beta-blockers) are used for hypertension, arrhythmias, and heart failure; they have no role in relaxing prostatic smooth muscle. * **Option C:** Anticholinergics (e.g., Oxybutynin) are used for overactive bladder. In BPH, they are generally avoided as monotherapy because they can decrease detrusor contraction and precipitate acute urinary retention. * **Option D:** PDE5 inhibitors (e.g., Tadalafil) can be used for BPH, but their mechanism involves increasing cGMP levels to relax smooth muscle, not alpha-receptor blockade. **NEET-PG High-Yield Pearls:** 1. **Uroselectivity:** Silodosin is more selective for α1A than Tamsulosin, leading to the lowest incidence of orthostatic hypotension among alpha-blockers. 2. **Side Effect:** The most characteristic side effect of Silodosin is **retrograde ejaculation** (due to relaxation of the vas deferens and ejaculatory duct). 3. **IFIS:** Like Tamsulosin, Silodosin is associated with **Intraoperative Floppy Iris Syndrome (IFIS)** during cataract surgery. Patients should be screened before surgery.

Q: How would a drug that competes with acetylcholine (ACh) for receptors at the motor end plate affect skeletal muscle?

Cause muscles to relax and be unable to contract. ### Explanation **1. Why the Correct Answer is Right:** The drug described is a **competitive (non-depolarizing) neuromuscular blocker**, such as **d-Tubocurarine** or **Vecuronium** [1]. These drugs act as antagonists at the **Nicotinic-M ($N_M$) receptors** located on the motor end plate of skeletal muscles [2]. By competing with Acetylcholine (ACh) for these receptor sites, they prevent ACh from binding. Since ACh cannot bind, the sodium channels do not open, the end-plate potential is not generated, and the muscle remains in a state of **flaccid paralysis** (relaxed and unable to contract) [3]. **2. Why the Incorrect Options are Wrong:** * **Option A & B:** These describe the effects of excessive cholinergic stimulation or **depolarizing blockers** (like Succinylcholine) in their initial phase [5]. If a drug were an *agonist* or an *Acetylcholinesterase inhibitor* (like Neostigmine), it would cause persistent depolarization, leading to spasms or "spastic" paralysis [1]. * **Option D:** A competitive antagonist *decreases* excitability by raising the threshold required for a nerve impulse to trigger a contraction. **3. NEET-PG Clinical Pearls & High-Yield Facts:** * **Reversibility:** The blockade caused by competitive blockers can be reversed by increasing the concentration of ACh. This is clinically achieved using **Acetylcholinesterase inhibitors** (e.g., **Neostigmine**) [1]. * **Sequence of Paralysis:** Small, rapidly moving muscles (eyes, fingers) are paralyzed first, followed by limbs, trunk, and finally the **diaphragm**. Recovery occurs in the reverse order. * **Drug of Choice:** **Rocuronium** is often preferred for rapid sequence intubation when Succinylcholine is contraindicated [4]. * **Sugammadex:** A novel reversal agent specifically for Rocuronium and Vecuronium that encapsulates the drug molecules, rendering them inactive.

Q: Which beta-blocker possesses intrinsic sympathomimetic activity?

Pindolol. ### Explanation **Concept: Intrinsic Sympathomimetic Activity (ISA)** Intrinsic Sympathomimetic Activity refers to the ability of certain beta-blockers to act as **partial agonists**. While they block the binding of endogenous catecholamines (epinephrine/norepinephrine), they simultaneously exert a low-level stimulant effect on the beta-receptors. This results in less resting bradycardia and less reduction in cardiac output compared to pure antagonists. **Why Pindolol is Correct:** **Pindolol** is the classic example of a non-selective beta-blocker with significant ISA. It is particularly useful in patients who require beta-blockade but are prone to excessive bradycardia or have a low resting heart rate. **Analysis of Incorrect Options:** * **A. Propranolol:** A prototype non-selective beta-blocker. It is a **pure antagonist** and lacks ISA. It is highly lipid-soluble and frequently used for migraine prophylaxis and performance anxiety. * **B. Atenolol:** A **selective Beta-1 blocker** (cardioselective). It is a pure antagonist without ISA and is water-soluble (renally excreted). * **C. Sotalol:** A non-selective beta-blocker that also possesses **Class III antiarrhythmic properties** (potassium channel blockade). It does not have ISA. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for ISA:** "**P**alpitation **A**nd **C**ardiac **L**evels" (**P**indolol, **A**cebutolol, **C**arteolol, **L**abetalol). * **Clinical Benefit:** Beta-blockers with ISA are less likely to cause lipid profile derangements (less effect on VLDL/HDL) and are preferred in patients with peripheral vascular disease (Raynaud's) because they cause less peripheral vasoconstriction. * **Contraindication:** They should be avoided in patients with angina or post-myocardial infarction, as the partial agonist activity may increase myocardial oxygen demand.

Q: Which beta-adrenoceptor blocking agent should be avoided in patients with renal failure?

Atenolol. **Explanation:** The primary factor determining the safety of beta-blockers in renal failure is their **lipid solubility (lipophilicity)**, which dictates their route of elimination. **1. Why Atenolol is the Correct Answer:** Atenolol is a **highly hydrophilic (water-soluble)** beta-blocker. Unlike lipophilic drugs, it is not metabolized by the liver and is excreted **unchanged by the kidneys**. In patients with renal failure, the clearance of atenolol is significantly reduced, leading to drug accumulation and an increased risk of toxicity (e.g., profound bradycardia and hypotension). Therefore, it must be avoided or require significant dose adjustment. **2. Analysis of Incorrect Options:** * **Metoprolol & Propranolol:** These are **lipophilic** beta-blockers. They undergo extensive hepatic metabolism (metabolized by the liver) and are excreted as metabolites. Their clearance is largely independent of renal function, making them safer choices in renal impairment. * **Esmolol:** This is an ultra-short-acting beta-blocker metabolized by **red blood cell esterases**, not the kidneys or liver. Its half-life remains unaffected by renal failure. **3. NEET-PG High-Yield Pearls:** * **Mnemonic for Lipid Solubility:** Remember **"PLM"** (Propranolol > Labetalol > Metoprolol) for high lipid solubility. These cross the Blood-Brain Barrier (BBB) and cause more CNS side effects like nightmares. * **Water-soluble Beta-blockers:** Atenolol, Sotalol, and Nadolol. These have long half-lives and require caution in renal failure. * **Drug of Choice:** For a patient with both renal failure and hypertension, **Metoprolol** or **Bisoprolol** (which has balanced hepatic/renal excretion) are generally preferred over Atenolol.

Q: A specific compound is derived from a plant. What condition is this compound used to treat?

Iridocyclitis. ***Iridocyclitis*** - **Atropine** from *Atropa belladonna* causes **mydriasis** and **cycloplegia**, preventing **posterior synechiae** formation in iridocyclitis. - It relieves **ciliary muscle spasm** and reduces pain associated with **iris inflammation**. *Glaucoma* - **Pilocarpine** or **physostigmine** (cholinergic agonists) are used for glaucoma to **constrict pupils** and increase aqueous humor outflow. - **Atropine** would worsen glaucoma by causing **mydriasis** and increasing **intraocular pressure**. *Tachycardia* - **Atropine** actually **causes tachycardia** by blocking **parasympathetic stimulation** of the heart. - It increases heart rate rather than treating elevated heart rate conditions. *Hyperpyrexia* - **Hyperpyrexia** is an **adverse effect** of atropine overdose due to impaired **thermoregulation**. - Atropine blocks **sweat glands** and can cause dangerous elevation in body temperature.

Question 1

A patient with glaucoma and bronchial asthma presents with status asthmaticus. What causative agent might have precipitated this condition?

Accepted Answer

Timolol eye drop

Answer

Pilocarpine eye drop

Answer

Betaxolol eye drop

Answer

Levobunolol eye drop

Question 2

What is the mechanism of action of Silodosin?

Accepted Answer

Alpha antagonist

Answer

Beta antagonist

Answer

Anticholinergic

Answer

PDE5 inhibitor

Question 3

How would a drug that competes with acetylcholine (ACh) for receptors at the motor end plate affect skeletal muscle?

Accepted Answer

Cause muscles to relax and be unable to contract

Answer

Produce uncontrolled muscle spasms

Answer

Cause the muscles to contract and be unable to relax

Answer

Make the muscles more excitable

Question 4

Which of the following agents does not affect near vision?

Accepted Answer

Adrenaline

Answer

Atropine

Answer

Homatropine

Answer

Pilocarpine

Question 5

Which of the following statements regarding 5-HT derivatives is true?

Accepted Answer

Sumatriptan's action is mediated by agonistic 5-HT 1B/1D receptor activity

Answer

Cisapride is a selective 5-HT4 antagonist

Answer

Ondansetron is a 5-HT3 agonist

Answer

Cyproheptadine is a 5-HT2A agonist

Question 6

Glycogenolysis is mediated by which receptors?

Accepted Answer

Alpha 1 and Beta 2 receptors

Answer

Alpha 1 receptor

Answer

Beta 2 receptor

Answer

Alpha 2 and Beta 1 receptors

Question 7

Which beta-blocker possesses intrinsic sympathomimetic activity?

Accepted Answer

Pindolol

Answer

Propranolol

Answer

Atenolol

Answer

Sotalol

Question 8

Which beta-adrenoceptor blocking agent should be avoided in patients with renal failure?

Accepted Answer

Atenolol

Answer

Metoprolol

Answer

Propranolol

Answer

Esmolol

Question 9

A specific compound is derived from a plant. What condition is this compound used to treat?

Accepted Answer

Iridocyclitis

Answer

Glaucoma

Answer

Tachycardia

Answer

Hyperpyrexia

Question 10

Combination of pilocarpine and epinephrine use in glaucoma treatment may inhibit which of the following?

Accepted Answer

Pigmented pupillary cyst

Answer

Retinal detachment

Answer

Vitreous haemorrhage

Answer

Iridocyclitis

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?